Scynexis (SCYX) Q3 2026 earnings review
Scynexis wins federal drug funding, but its cash burn rises
Scynexis, a developer of medicines for rare kidney and fungal diseases, cleared early safety trials for both drugs while burning more cash. Operating loss widened 16% to $10 million as clinical spending grew, though tax credits kept the bottom-line loss steady. Chief executive David Angulo plans to start a mid-stage kidney trial this year, while a federal contract provides $19 million initially for its antifungal drug.
| Loss from operations | $9.8M +16% from a year ago |
|---|---|
| Cash and investments | $63.2M down $7.9M from June |
| BARDA antifungal contract | Up to $214M $18.5M in initial base period |
| Cash runway outlook | Into 2029 implies max $7M quarterly burn by our math |
⚖️ Verdict: 🟢 Bullish
The story got better because the government contract and Phase 1 results turn two early drug candidates into mid-stage clinical programs. Hiring two kidney specialists from Akebia Therapeutics also prepares the team for the polycystic kidney disease study. One caution: the company nearly doubled its share count over the past year to raise cash, and its third-quarter cash drain exceeded the pace needed to reach 2029.
The question now is whether federal reimbursements will slow the quarterly cash drain once both Phase 2 trials begin. If government payments cover most of the antifungal trial, cash can last into 2029; if patient enrollment drives clinical bills higher, the drugmaker will need more capital. Fourth-quarter cash and trial startup costs will provide the first test.
🐂 Bull Case
Federal Contract Funds the Antifungal Drug Program
Scynexis is developing SCY-247, a second-generation antifungal medicine for severe fungal infections, alongside its main kidney program. Chief executive David Angulo said the partnership lets the rare-disease biotech advance the drug "while leveraging our existing infrastructure and capabilities".
On September 28, the Biomedical Advanced Research and Development Authority (BARDA, a US government agency) awarded the company a contract worth up to $214 million. The initial base award provides $18.5 million, or 8.6% of the total by our math, to move oral and intravenous SCY-247 into a Phase 2 trial for invasive candidiasis (a bloodstream yeast infection). In October, the drug passed a 56-person Phase 1 intravenous study, hitting target blood levels at doses of 50 mg or higher without serious side effects.
The federal award matters because it pays for a second clinical pipeline without forcing the drugmaker to choose between its two main medicines. However, the deal is a cost-share arrangement, and the government must exercise future contract options for the remaining $195.5 million to arrive.
What to watch: regulatory agreement with the Food and Drug Administration to start the Phase 2 SCY-247 trial in 2027. Clearing that hurdle unlocks the next stage of trial work and tests whether the initial $18.5 million covers most of the early study bill.
Lead Kidney Drug Cleared Phase 1 Safety
"We are working to advance SCY-770 into a Phase 2 proof-of-concept clinical trial by the end of this year," chief executive David Angulo said. SCY-770 is an oral drug that activates AMPK (an enzyme that regulates cellular energy) to treat autosomal dominant polycystic kidney disease (ADPKD, an inherited condition where fluid-filled cysts destroy the kidneys). Angulo noted that the drug was "well tolerated at higher doses than previously evaluated".
On October 6, the New Jersey biotech finished a Phase 1 trial in 25 healthy volunteers who took up to 750 mg once daily or 500 mg twice daily for seven days. The only approved rival drug in the United States, Jynarque, generated about $1.5 billion in 2024 sales despite safety and liver-monitoring limits. Because SCY-770 showed clean safety at higher doses, management has the dosing data needed to test the pill in actual kidney patients.
What to watch: the first patient dosed in the Phase 2 ADPKD study in the fourth quarter of 2026, followed by an interim efficacy readout in the fourth quarter of 2027. Starting on time keeps the late-2027 readout on schedule.
🐻 Bear Case
Cash Burn Exceeds the 2029 Runway Pace
Scynexis ended September with $63.2 million in cash, short-term investments and long-term bonds, down from $71.1 million in June. The company stated that this balance is "sufficient to continue operations into 2029" and that it will pay its share of near-term SCY-247 costs "within its existing operating plan".
- Third-quarter cash decrease: $7.9 million, or 11.1% of the June balance by our math
- Maximum burn to reach 2029 (nine quarters): $7.0 million per quarter by our math
- Clinical trial spending in the third quarter: up $1.7 million from a year ago
- License revenue from partner GSK: $0, down from $0.3 million a year ago
The third-quarter cash drain contradicts the comfort of a 2029 runway because spending is already above the $7.0 million quarterly pace before either Phase 2 trial has begun. Enrolling patients in the SCY-770 kidney trial this quarter and starting the SCY-247 cost-share trial next year will push clinical bills higher unless federal reimbursements arrive quickly.
What to watch: fourth-quarter cash and investments alongside initial BARDA contract billings. A quarterly cash drop above $7 million would show that the 2029 target relies on raising more money or slowing trial work.
Equity Sales Nearly Doubled the Share Count
To keep its bank balance above $60 million while funding drug trials, the clinical-stage drugmaker issued a large block of new stock during the first nine months of 2026. That equity raise boosted total cash and investments by 12.4% from the end of 2025, by our math, even after covering nine months of operating losses.
Weighted average shares in the third quarter jumped 89.9% from a year ago to 11.84 million, while actual shares issued on the balance sheet rose 82.9% since December to 9.95 million. The gap between the 11.84 million weighted average and the 9.95 million common shares indicates that pre-funded warrants are also sitting in the per-share count. Additional paid-in capital climbed by $32.0 million over those nine months, and the balance sheet still carries $0.6 million in deferred offering costs.
Because each share now represents nearly half as much ownership of the pipeline as it did a year ago, future milestones from the GSK partnership or kidney trials are split across almost twice as many shares.
What to watch: fourth-quarter weighted average shares and any new offering activity. Further share sales while $0.6 million of deferred offering costs sit on the books would dilute existing holders again before Phase 2 data arrives.
Tax Credits Hid a Wider Operating Loss
Reported net loss narrowed by 1.5% from a year ago to $8.5 million, and loss per share dropped by 48.6% to $0.71. However, those headline figures made the quarter look cheaper than the actual work inside the laboratories.
Loss from operations widened by 16.1% to $9.8 million because research and development spending rose 13.7% to $6.2 million and license revenue dropped from $0.3 million to zero. Clinical trial spending jumped by $1.7 million, while preclinical and manufacturing work fell by $1.0 million combined. Below the operating line, the biotech booked $0.9 million in other income from "certain research and development tax credits" and a smaller warrant liability charge. Excluding the tax credit and warrant swing, the loss grew 15.0% by our math.
What to watch: research and development expense in the fourth quarter as the Phase 2 kidney study begins. Without another tax credit, the bottom-line loss will rise to match the expanding clinical budget.
👓 Other Themes
Kidney Specialists Join the Executive Ranks
In September, Scynexis hired Sanjay Subramanian as finance chief following the retirement of Ivor Macleod, and named nephrologist Todd Minga to lead research and development. It also appointed Steven Burke, formerly research chief at kidney drugmaker Akebia Therapeutics, to the board alongside Minga, who also came from Akebia. Meanwhile, the company said partner GSK "continues making progress toward the relaunch of BREXAFEMME", which carries up to $146 million in potential sales milestones.
💲 Other KPIs
Both working-capital lines expanded since December 2025 as trial preparations ramped up. Accounts payable (unpaid bills to vendors and trial sites) rose 61.8% from $2.23 million at year-end, while prepaid expenses jumped more than ninefold from $0.26 million to $2.43 million.
Overhead spending rose 8.4% from $3.29 million a year ago. The $0.28 million increase came mainly from $0.2 million in higher professional fees during a quarter when the biotech replaced its finance chief and expanded its executive team.
🔮 Guidance
New. Management expects its $63.2 million in cash and investments to fund operations into 2029, including its cost-share portion of the SCY-247 trial. By our math, stretching $63.2 million across the nine quarters from September 2026 to early 2029 allows an average cash drain of at most $7.0 million per quarter, below the $7.9 million spent in the third quarter.
❓ Key Questions
What is Scynexis's dollar share of SCY-247 trial costs?
The BARDA contract provides $18.5 million in its base period under a cost-share structure, and the company plans to fund its share from existing cash. Management has not disclosed the cost-share ratio or the total budget for the Phase 2 candidiasis study.
Why were weighted shares 1.9 million higher than issued shares?
Third-quarter weighted average shares reached 11.84 million, while common shares issued and outstanding on September 30 stood at 9.95 million. Investors need the exact count of pre-funded warrants and options included in the per-share calculation.
When will GSK relaunch Brexafemme?
The release repeats that GSK is making progress toward relaunching the licensed antifungal pill, which carries up to $146 million in sales milestones. Management gave no timeline, regulatory milestones, or manufacturing dates for when royalty cash might start.
How many patients and doses will the kidney trial test?
SCY-770 enters its Phase 2 proof-of-concept study in polycystic kidney disease this quarter with an interim readout in late 2027. The company has not yet shared the target enrollment size, the chosen dose from Phase 1, or the primary biomarker endpoint.